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Abstract: The polysaccharide-containing extracellular fractions (EFs) of the edible 
mushroom  Pleurotus ostreatus have immunomodulating effects. Being aware of these 
therapeutic effects of mushroom extracts, we have investigated the synergistic relations 
between these extracts and BIAVAC and BIAROMVAC vaccines. These vaccines target 
the stimulation of the immune system in commercial poultry, which are extremely 
vulnerable in the first days of their lives. By administrating EF with polysaccharides from 
P. ostreatus to unvaccinated broilers we have noticed slow stimulation of maternal 
antibodies against infectious bursal disease (IBD) starting from four weeks post hatching. 
For the broilers vaccinated with BIAVAC and BIAROMVAC vaccines a low to almost 
complete lack of IBD maternal antibodies has been recorded. By adding 5% and 15% EF in 
the water intake, as compared to the reaction of the immune system in the previous 
experiment, the level of IBD antibodies was increased. This has led us to believe that by 
using this combination of BIAVAC and BIAROMVAC vaccine and EF from P. ostreatus 
we can obtain good results in stimulating the production of IBD antibodies in the period of 
the chicken first days of life, which are critical to broilers’ survival. This can be 
rationalized by the newly proposed reactivity biological activity (ReBiAc) principles by 
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examining the parabolic relationship between EF administration and recorded biological 
activity. 
 
Keywords: extracellular fraction; Gumboro disease; BIAVAC & BIAROMVAC vaccines; 
ReBiAc principles 
 
 
1. Introduction 
 
Traditionally, many types of mushrooms have been used as Traditional Chinese Medicine, as well 
as functional foods in Japan and other Asian countries. Edible mushrooms have beneficial health 
effects and in the treatment of some diseases thanks to their immunomodulatory, anti-neoplastic, anti-
hyperglycemic and lipid-reducing properties [1,2]. In this way, water extracts of the Shiitake 
mushroom (Lentinus edodes), for example, have been shown to prevent tumors in mice. Mushroom  
(P. ostreatus) polysaccharides especially the high-molecular-weight β-D-glucan, have been considered 
to have anti-cancer activity [3]. These mushroom polysaccharides also exhibited direct inhibitory 
effects on cancer cell growth by modulating cell-cycle progression and inducing apoptosis [3–5].  
Polysaccharides represent a structurally diverse class of macromolecules of relatively widespread 
occurrence in Nature. The biological activities of polysaccharides have attracted more and more 
attention in biochemistry and medicine. Many immunomodulation and antitumoral polysaccharides 
were isolated from mushrooms and extensively studied in Japan, China, and Europe [3].  
Many polysaccharides purified from mushroom fungi are either homoglycans or heteroglycans, 
while others mostly bind to protein residues as polysaccharide-protein complexes. The fungal 
antitumor polysaccharides are mainly present as glucans with different types of glycosidic linkages, 
but some are true heteroglycans. The main source of immunomodulation and antitumor 
polysaccharides appears to be related to fungal cell walls which consist of polysaccharides such as 
chitin, cellulose, (1→3),(1→6)-β-glucans and (1→3)-α-glucans or polysaccharide-protein complexes 
such as galactomannan-protein or glucuromannan-protein. Several potent antitumor polysaccharide-
protein complexes have been purified from fruiting bodies of a Chinese edible mushroom,   
P. sajor caju. The polysaccharide with strong antitumor activity isolated from P. ostreatus is a highly 
branched (1→3)-β-glucan having an average structure represented by a pentasaccharide segment 
consisting of one nonreducing terminus, on 3,6-O-substituted, and three 3-mono-O-substituted  
β-glucopyranosyl side chains [3].  
It is known that an unbalanced immunitory system provides the premise for a great number of 
diseases in both humans and animals. Infectious bursal disease (IBD) is caused by a virus that is a 
member of the genus Avibirnavirus of the family Birnaviridae. According to the virus virulence and 
pathogenicity, IBD causes more severe or less severe lesions on the bursa of Fabricius and other 
organs such as spleen, thymus and kidneys, and may induce immunosuppression and mortality in 
birds. Infectious bursal disease virus (IBDV) causes clinical disease of considerable economic 
importance in chickens, usually between 3 and 6 weeks of age or possibly older, following infection 
with very virulent strains. Numerous vaccines and vaccination programs have been studied and Int. J. Mol. Sci. 2009, 10                 
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proposed worldwide [6–8]. The effect of polysaccharides present in EF extracts from the edible 
mushroom P. ostreatus are investigated here with emphasis on the specific response of the chickens’ 
immunitary system. The following points have been investigated: (1) the effect of EF on unvaccinated 
chickens, (2) the effect of EF on broilers vaccinated with BIAVAC vaccine, (3) the effect of EF  
on broilers vaccinated with BIAROMVAC vaccine and (4) the parabolic reactivity analysis of 
biological activity. 
By comparing the results, we have showed that EF from the edible mushroom P. ostreatus helps 
BIAVAC and BIAROMVAC vaccines in stimulating the immune system against IBDV during the 
critical first two weeks post hatching. 
 
2. Results and Discussion 
 
2.1. The effect of EF on unvaccinated chickens 
 
In our study, we have followed the effect of EF from the edible mushroom P. ostreatus on broiler 
chickens which have not been vaccinated with BIAVAC and BIAROMVAC vaccines (Figure 1). In 
this case the maternal titers of infectious bursal disease virus antibodies (IBD–AB) (control) are seen 
to decrease, being at the minimum level (96) in four weeks post hatching (Figure 1a). This antibody 
titer (96) was below the estimated cut-off level in this enzyme–linked immunosorbent assay (ELISA) 
system.  
 
Figure 1. The effect of different concentrations of EF from P. ostreatus upon the maternal 
IBD–AB titer for unvaccinated chicken. Thin trend line —: the titer of maternal IBD–AB 
(Control); Thick trend line ▬: the titer of maternal IBD–AB in un-vaccinated chicken  
NV + 5% (a) and 15% EF (b). Weeks mean weeks post hatch.  
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Figure 1. Cont. 
 
 
By analyzing the variation (Table 1) we can observe significant differences (p<0.001) in the change 
of IBD–AB maternal titer. The variation coefficient is low (5.97%) in the first week of chicken life and 
high (20.37%) in week four.  
 
Table 1. The effect of different concentration of EF from P. ostreatus upon IBD–AB titre 
uppon non-vaccinated (NV) chicken in terms of average ±  standard deviation (SD), and 
coefficient of variation (defined as the ratio:  Average SD / ). 
Experimental Source  Time (weeks)  Average ± SD  Coefficient of variation 
 1  5173.0
a ± 308.97  5.97% 
Control 2  3332.05
a ± 260.47  7.81% 
 3  754.0
a ± 48.11  6.38% 
 4  96.0
a ± 19.55  20.37% 
 5  0.0   
 1  5104.0
b ± 411.60  8.06% 
NV + 5%EF  2  4532.1
 b ± 545.55  12.04% 
 3  1101.05
 b ± 234.18  21.26% 
 4  899.0
 b ± 52.11  5.797% 
 5  1843.0
 b ± 12.51  0.67% 
 1  5098.0
 b ± 187.98  3.68% 
NV + 15%EF  2  4166.0
 b ± 426.17  10.22% 
 3  2173.0
 b ± 316.00  14.54% 
 4  1548.85
 b ± 111.37  7.19% 
 5  1949.9
 b ± 148.84  7.63% 
a p<0.001,
b p<0.0001. 
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The F-ratio, which in this case equals 3152.98, is a ratio of the between-group estimate to the 
within-group estimate. Since the P-value of the F-test is less than 0.05, there is a statistically 
significant difference between the means of the five weeks at the 95.0% confidence level. If we 
compare the distribution of maternal antibodies within each group during one week, but also between 
weeks, we can notice a significant difference (Table 2).  
The difference between the antibodies titer averages in weeks four and five is not significant. Yet, 
by adding 5% EF in the water intake, we can notice a stabilization of the titer level for the stimulation 
of production of maternal IBD–AB, starting with the first days of week five (p<0.0001). The standard 
deviation from the average of the maternal IBD–AB  titer value  is high in the mid-period of our 
experiment (21.26% in week three) and low (0.67%) in the last week (Table 1).  
The differences between the antibody titer averages between groups are significant, but those 
between the values of weeks three and four are insignificant. They are significant, but negative, 
between the average values of weeks three and five (-741.95) and between weeks four and five 
(-944.0) (Table 2). This last aspect has been shown by stimulation of antibodies production (Figure 1a) 
and is statistically explained by the chicken positive reaction (r=0.94) to EF action for IBD–AB 
stimulation and a homogeneity of broilers answers (biological activity) in IBD–AB production. 
Table 2. The significant differences of IBD–AB titre environment between titre groups  
to non-vaccinated (NV) broilers and treated with EF from P. ostreatus at 95.0%   
confidence level. 
The pairs means  
of IBD–AB 
Control  NV + 5% EF  NV + 15% EF 
1–2 1840.95*  571.90*  932.00* 
1–3 4419.00*  4002.95*  2925.00* 
1–4 5077.00*  4205.00*  3549.15* 
1–5 5173.00*  3261.00*  3148.10* 
2–3   2578.05*  3431.05*  1993.00* 
2–4 3236.05*  3633.10*  2617.15* 
2–5 3332.05*  2689.10*  2216.10* 
3–4 658.00*  202.05  624.15  * 
3–5 754.0*  -741.95*  223.10* 
4–5 96.0  -944.00*  -401.05* 
* denotes a statistically significant difference. 
 
By supplementing the water intake with 15% EF from P. ostreatus (Figure 1b), standards deviations 
are low at the beginning of the experiment (3.68%) and towards the end of it (7.19% and 7.63%). The 
differences between antibodies titre averages between all averages antibodies groups are significant. A 
positive ratio (r=0.99) has been established between the two variables, EF and the capacity of chicken 
bodies to produce antibodies (Figure 1b). The unvaccinated broilers + 5% EF have shown a better 
global behaviour, whose average of variation coefficient has been 9.56%, respect to both the 
unvaccinated broilers + 15% EF with an average of 8.65% and those unvaccinated without EF, which 
show an average of about 8.106%.  
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2.2. The effect of EF on broiler vaccination with BIAVAC vaccine 
 
In this experimental group, we have followed the change of IBD–AB antibodies in broilers 
vaccinated with BIAVAC and treated with EF. Thus, all broilers, although vaccinated with BIAVAC, 
without EF treatment, have shown a decrease of the level of maternal IBD–AB antibodies. The lowest 
antibody titre (185) was below the estimated cut-off level in this ELISA system. The production of 
antibodies increased starting with week 4 (p<0.0001; Figure 2a; Table 3).  
 
Figure 2. The effect of different concentration of EF from P. ostreatus upon maternal  
IBD–AB titre to broilers vaccinated with BIAVAC. Thin trend line —: the titre of maternal 
IBD–AB (BIAVAC); Thick trend line ▬: the titre of maternal IBD–AB to broilers with 
BIAVAC + 5% (a) and BIAVAC + 15% EF(b). Weeks mean weeks post hatch, with the 
vaccination at the end of week 1. 
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The final level of this biosynthesis of antibodies is above the value of the titre on the 1
st day. By 
treating the intake water with 5% EF, the values of IBD–AB titre are maintained at a relatively high 
level (p<0.0001), with slightly high indicators of variation coefficient, at the beginning and at the end 
of the treatment. We can notice (Figure 2a; Table 3) the action of EF in synergism with BIAVAC 
vaccine upon the production of antibodies (r=0.93). The standard deviations are significant when 15% 
EF was administered (p<0.0001; Figure 2b, Table 3).  
 
Table 3. The effect of different concentration of EF from P. ostreatus upon IBD–AB titre 
to broilers vaccinated with BIAVAC vaccine.  
Experimental 
Source 
Time 
(weeks) 
Average
*  Standard 
deviation 
Coefficient of 
variation** 
 1  3332.05  260.476  7.81% 
BIAVAC 2  1157.05  111.922  9.67% 
 3  185.00  35.9444  19.42% 
 4  2374.00  333.598  14.05% 
 5  3859.0
 0 278.548  7.21% 
 1  3700.00  545.832  14.75% 
BIAVAC + 
5%EF 
2 2097.00  395.180  18.84% 
 3  2423.10  224.396  9.26% 
 4  3195.05  604.461  18.91% 
 5  4107.00  495.521  12.06% 
 1  4166.00  426.172  10.22% 
BIAVAC + 
15%EF 
2 3006.05  389.239  12.94% 
 3  2794.05  376.687  13.48% 
 4  4155.00  587.624  14.14% 
 5  5170.05  961.208  18.59% 
* p<0.0001; ** (SD/Average). 
 
By a multiple comparison between the pairs means of IBD–AB: 1–2, 1–3 and 1–4 which 
correspond to the immunosuppressive period (weeks 1 and 3), we can notice significant positive 
differences with the BIAVAC experiment. Starting with week 4, between the pairs means of IBD–AB, 
we can notice significant negative differences (Table 4). In this 2
nd half of the experimental period, the 
production of IBD–AB antibodies can be noticed, with a high level (3859.00), which is above the level 
of the 1
st day of post hatching. In the next experimental variants of the broilers (BIAVAC + 5% EF and 
BIAVAC + 15% EF ), between the pairs means of IBD–AB we can notice significant differences of 
value, as compared to BIAVAC variants at the 95.0% confidence level (Table 4).  
The averages of variations are relatively homogenous, 11.63% (BIAVAC non-EF), 14.76% 
(BIAVAC + 5% EF) and 13.87% (BIAVAC + 15% EF), while the correlation coefficients between the 
variables of the system are positive, r=0.93 (BIAVAC + 5% EF) and r=0.95 (BIAVAC + 15% EF) 
(Figures 2a,b).  
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Table 4. The significant differences of IBD–AB titre means between titre groups in 
broilers vaccinated with BIAVAC vaccine and treated with EF from P. ostreatus at 95.0% 
confidence level. 
The pairs means 
of IBD–AB 
BIAVAC 
BIAVAC + 5% 
EF 
BIAVAC + 15% 
EF 
1–2 2175.00*  1603.00*  1159.95* 
1–3 3147.05*  1276.90*  1371.95* 
1–4   958.05*  504.95* 11.00 
1–5 -526.95*  -407.00*  -1004.05* 
2–3   972.05*  -326.10*  212.00 
2–4 -1216.95*  -1098.05*  -1148.95* 
2–5 -2701.95*  -2010.00*  -2164.00* 
3–4 -2189.00*  -771.95*  -1360.95* 
3–5 -3674.00*  -1683.90*  -2376.00* 
4–5 -1485.00*  -911.95*  -1015.05* 
*denotes a statistically significant difference. 
 
2.3. The effect of EF on broilers vaccinated with BIAROMVAC vaccine 
 
In this experiment, we have followed the production of IBD–AB antibodies in non-vaccinated 
chickens, vaccinated with BIAROMVAC, as compared to the ones under BIAROMVAC + 5% EF 
treatment and BIAROMVAC + 15% EF treatment, respectively. Thus, in chickens only vaccinated 
with BIAROMVAC vaccine, (like BIAVAC vaccine for the previous experiment), we can notice the 
temporary suppressive action of maternal IBD–AB antibodies production, in the first two weeks post- 
vaccinated inoculation (Figures 3a,b). All broilers had a maternal IBD–AB titer of 217 in the ELISA. 
These antibodies were below the estimated cut-off level in this ELISA. In the experimental groups, to 
which we have added 5% and 15% EF, respectively, all along the duration of the experiment, the 
antibodies level remained high, with a slow decrease at the beginning of the treatment (Figure 3,  
Table 5; p<0.0001).  
We have noticed a better response in broilers treated with BIAROMVAC + 5%EF, whose average 
variation was 12.85%, as compared to the treatments BIAROMVAC without EF and BIAROMVAC + 
15% EF, with averages of 14.39 and 14.02%, respectively. By comparison, the all pairs means of 
maternal IBD–AB have shown significant differences at 95.0% confidence level   
(Table 6), except for one case (2–4) of the treatment with BIAROMVAC + 5% EF and two cases  
(1–4 and 1–5) of the treatment with BIAROMVAC + 15% EF. The correlation coefficient between the 
system variables are positive (r=0.92 and respectively, r=0.80) (Figures 3a,b).  
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Figure 3. The effect of different concentrations of EF from P. ostreatus upon maternal 
IBD–AB titer in broilers vaccinated with BIAROMVAC vaccine. Thin trend line —: the 
titre of maternal IBD–AB (BIAROMVAC); Thick trend line ▬: the titre of maternal IBD–
AB in broiler BIAROMVAC + 5% (a) and BIAROMVAC + 15% EF (b). Weeks mean 
weeks post hatch, with the vaccination at the end of week 1. 
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Table 5. The effect of different concentrations of EF from P. ostreatus upon IBD–AB titer 
in chickens treated with BIAROMVAC vaccine. 
Experimental Source 
Time 
(weeks) 
Average
*  Standard 
deviation 
Coefficient of 
variation 
 1  3326.05  257.70  7.74% 
BIAROMVAC 2  1361.00  258.27  18.97% 
 3  217.00  45.23  20.84% 
 4  2602.05  319.18  12.26% 
 5  3799.05  460.48  12.12% 
 1  3725.40  547.11  14.68% 
BIAROMVAC + 5% 
EF 
2 2842.00  462.71  16.28% 
 3  2359.00  208.15  8.824% 
 4  2982.05  334.84  11.22% 
 5  3448.00  457.18  13.25% 
 1  4184.70  424.25  10.13% 
BIAROMVAC + 15% 
EF 
2 2608.00  442.78  16.97% 
 3  3238.00  345.98  10.68% 
 4  3879.00  738.68  19.04% 
 5  4161.00  553.71  13.30% 
*p<0.0001. 
 
Table 6. The significant differences of IBD–AB means titer between titer groups in 
broilers vaccinated with BIAROMVAC and treated with EF from P.ostreatus at 95.0% 
confidence level. 
The pairs means 
of IBD–AB 
BIAROMVAC 
BIAROMVAC  
 + 5% EF 
BIAROMVAC  
 + 15% EF 
1–2 1965.05*    883.40*  1576.7* 
1–3 3109.05*  1366.40*    946.7* 
1–4 724.00*    743.35*  305.7 
1–5  -473.00*   277.40*   23.7 
2–3 1144.00*    483.00*  -630.0* 
2–4 -1241.05*  -140.05  -1271.0* 
2–5 -2438.05*    -606.00*  -1553.0* 
3–4  -2385.05* -623.05* -641.0* 
3–5  -3582.05* -1089.00* -923.0* 
4–5 -1197.00*    -465.95*  -282.0 
*denotes a statistically significant difference. 
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The real guideline basis of this experiment relies on the immunosuppressive effects in non- 
vaccinated chickens by BIAVAC, BIAROMVAC vaccines, and other IBDV vaccines in the first 
critical days of broilers life [9,10]. The field and clinical observations have shown differences in 
response of different lines genetic backgrounds upon the influence of some IBDV pathogenesis upon 
maternal antibodies. Also, from economical reasons, the studies are worth initiated and continued since 
the production of broilers decreases because of maternal antibodies decrease in progenies   
(Tables 1, 3, 5). Another reason of these studies reflects the fact that not much is known as far the 
immunosuppressive abilities of IBD vaccines in commercial broilers is concerned [11–13]. In the 
present work, we compared immuno-modulatory effects of different concentrations of EF with 
polysaccharides extracted from P. ostreatus with, but also without BIAVAC and BIAROMVAC 
vaccines, on commercial broilers. Our study proves the immunomodulatory ability of EF with 
polysaccharides extracted from P. ostreatus together with BIAVAC and BIAROMVAC vaccines, 
towards the stimulation of IBD–AB antibodies production. 
There are studies which demonstrate, to a certain degree of certitude, the existence of some 
connections between IBDV–induction of immunosuppression and the severe injuries which appear in 
bursa of Fabricius. Even more, there have been situations, even as hypothesis, of association of IBDV 
with B cells, macrophages and follicular dendritic cells in bursa and spleen [8]. Other fundamental 
studies mention that these IBD–AB vaccines may induce suppressive secondary effects in the immune 
system, such as systemic T cell activity. Thus, the macrophages may induce the release of cytokines 
and nitric oxide which can suppress T cell activity. Another hypothesis is that the suppression of T 
helper cell activity might favour to reduce IBD–AB antibodies response in broilers [14]. Also in the 
cases of our research, we have noticed such a temporary suppression of IBD–AB antibodies in all 
experiments in broilers (Figure 1–3), when we have used BIAVAC and BIAROMVAC vaccines. By 
supplementing the water intake with EF which has polysaccharides extracted from P. ostreatus we have 
noticed a stimulation of IBD–AB antibodies production in all experimental groups. Scientific data show 
that substances from edible mushrooms are responsible for imunodulating effects. These substances are 
β-D-glucan polysaccharides. The β-D-glucans are a heterogeneous group of glucose polymers. These 
polysaccharides are the major cells wall structural components found in fungi and also present in plant 
and some bacteria. Studies with β-D-glucan from P. ostratus or from L. edodes, have shown several 
immuno-modulatory properties which include increase of T-cells activity, restoration of T-helper cells 
suppression, induction of cytotoxic activity of peritoneal macrophages. The β-glucans bind to receptors 
on cells membranes of macrophages, neutrophils, natural killer cells, T-cells dendritic cells, fibroblast 
and vascular endothelial cells. The molecular structure of these substances from fungi influences the 
affinity to receptors and the stimulation of the immunomdulator system [15,16].  
 
2.4. Reactivity analysis of the parabolic biological activity relationship  
 
The results of previous sections opens the possibility for further systematic treatment of IBD–AB 
activity (y) through employing the fitted response curves of Figures 1–3 beyond the statistical 
correlation factor and fitted parameters.  
Actually, since the reported ANOVA analysis in Figures 1–3 unfolds under the parabolic form: Int. J. Mol. Sci. 2009, 10                 
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2
0 bx ax y y + − =   (1) 
it readily reminding of the chemical reactivity law modeling the (molecular) systems’ energy change 
with the number of donated/accepted electrons  N Δ : 
( )
2 N N E E m equilibriu Δ + Δ − = η χ   (2) 
through the electronegativity χ  and chemical hardness η  indices: 
2
EA IP +
= χ   (3a) 
2
EA IP−
= η   (3b)
in terms of ionization potential (IP) and electron affinity (EA), respectively [17]. 
Now, the idea is to rearrange Equation (1) under the equivalent form given by Equation (2) that will 
reveal us how the fitting coefficients of Equation (1) will correspond to the reactivity indices in 
Equation (2). Yet, such transformation is not direct, but upon considering appropriate operations. As 
such, the first step regards the translation of the form given by Equation (1) into a parabolic form 
centred on its optimum values, either for dependent  opt Y  and independent  opt X  variables:  
( )
2 ) ( opt opt opt X x X x Y Y − + − − = β α   (4) 
while the optimum expression are found by the variation of Equation (1): 
0 : =
∂
∂
= opt X x
opt x
y
X ,  ( ) opt opt X y Y =   (5) 
or, analytically as: 
b
a
X opt 2
= , 
b
a
y Yopt 4
2
0 − =   (6) 
Then, in order for coefficients α  and  β   to play the “reactive” role in Equation (4) as 
electronegativity and chemical hardness do in Equation (2), respectively, they have to be considered 
with a similar expression as that of Equation (3), namely: 
2
+ − +
=
Y Y
α ,  (7a) 
2
+ − −
=
Y Y
β ,  (7b)
however, linked with the input equation (1) by means of assignments:  
( ) opt Y y x y Y → − → =
−
0 ; 1 ,  (8a) 
( ) opt Y y x y Y → + → =
+
0 ; 1 ,  (8b)
thus providing the results: Int. J. Mol. Sci. 2009, 10                 
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b
b
a
y b Yopt + − = + =
4
2
0 α ,  (9a) 
a = β .  (9b)
Now, paralleling the chemical reactivity principles of electronegativity and chemical hardness [17] 
to the coefficients α and β of Equation (4), respectively, one can infer the hierarchies among two 
biological-chemical tested systems for which the two pairs of coefficients, say () I I β α ,  for the system 
“I” and () II II β α ,  for the system “II”, have been computed. 
The electronegativity principles would lead with the rule that as the α index of a system is higher as 
the system will display larger reactivity/activity, here translated as growing of the antibody metabolic 
action; in short: “as α increases as grows the biological activity”, i.e., the stimulation of antibody 
synthesis; this may be eventually called as The First Principle of Reactive Biological Activity 
(ReBiAc1). 
Instead, the chemical hardness principles, especially the maximum hardness one [17], would lead 
with the idea that the β factor tendency is detrimental to the biological activity, or, analytically: “as β 
increases as slows the biological activity”, here - the immunological action; this may be eventually 
called as The Second Principle of Reactive Biological Activity (ReBiAc2). 
Table 7 collects all the fitted and reactive biological activity (ReBiAc) data from the Figures 1–3 
and the equations (1)–(9), respectively; it allows a global view of the experiments either between 
groups with various EF belonging to the same vaccine or not-vaccinated chickens. Furthermore, the 
present ReBiAc analysis finely clarifies upon the hierarchy of experiments in providing viable 
biological activity (here viewed as the potency of antibody synthesis). For instance, if one looks to the 
ordering correlation factors from the experimental systems I–IX (of Table 7) there finds the puzzling 
hierarchy: 
2 2 2 2 2 2 2 2 2
I III VI VIII IV V VII II IX R R R R R R R R R < < < < < < < <   (10) 
while this is rearranged in terms of increasing beneficial activity by the ReBiAc1 principle: 
4 3 42 1 4 3 42 1 4 3 42 1 4 43 4 42 1
%) 15 ( %) 5 ( EF VAC
VI IX
EF VAC
VIII V
EF VAC UN
III II
CONTROLS ALL
VII IV I
+ + + −
< < < < < < < < α α α α α α α α α  
(11) 
or as the decrease of antagonist activity in the light of ReBiAc2 principle: 
4 3 42 1 4 3 42 1 4 43 4 42 1 4 3 42 1
EF BIAROM
IX VIII
EF BIA
V VI
VACCINATED UN
III I II
VAC CONTROL
VII IV
+ + − −
> > > > > > > > β β β β β β β β β  
(12) 
From both these chains of bio-activity orderings appears the decisive influence EF has on anti-
bursal vaccines since placed on the extreme of ReBiAc principles’ records (maximums for α, and 
minimums for β values).  
This way, the analytical and conceptual tools for cross-judging both the favourable and detrimental 
(natural or induced) biological actions were formulated and tested. Moreover, is phenomenologically 
proven that each biological system described by a parabolic dependency contains the intrinsic positive 
(beneficial) and negative (detrimental) effects at the metabolic level, however in different degree. 
Nevertheless, the actual study shows how the beneficial influence may be adjusted to prevail on the Int. J. Mol. Sci. 2009, 10                 
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harmful one by controlling the induced biological activity, here through administrating various EF 
with polysaccharides from Pleurotus. 
 
Table 7. The computed favourable and detrimental biological activity factors, α and β, 
according with their definitions given by Equation (9), for titers vs. weeks fitted curves 
displayed in Figures 1–3, employing the specific parabolic data modelled by Equation (1). 
Experimental 
System/Source 
Fitted Parameters  Activity parameters
a b y0 R
2  α  β 
U
N
-
 
V
A
C
  I.  Control 3676.8 386.43 8650.6 0.9809 291.04 3676.8 
II.  EF (5%)  3698.8 447.21 8872.8 0.8368 1671.97  3698.8 
III.  EF (15%)  2620.6 288.21 7678.6 0.9435 2009.74  2620.6 
B
I
A
V
A
C
 
V
A
C
  IV.  Control 4264.8 748.64 6740.6 0.9079 1415.39 4264.8 
V.  EF (5%)  2155.7 391.14 5268.8 0.8806 2689.75  2155.7 
VI.  EF (15%)  2222.7 423.07 5872.6 0.9309 3376.3  2222.7 
B
I
A
R
O
M
V
A
C
  VII.  Control 4004  703.79 6531.4 0.8616 1540.3 4004 
VIII. EF (5%)  1671.7 271.71 5097.4 0.924  2797.82  1671.7 
IX.  EF (15%)  1474.8 266.21 5110  0.6182 3333.62  1474.8 
 
3. Experimental Section 
 
3.1. Materials and methods 
 
3.1.1. Microorganisms and media 
 
A culture of P. ostreatus was isolated from a mountainous district in Banat (Romania). As a result 
of multiple selections in the Laboratory of Plant Biotechnology, West University of Timisoara, we 
have obtained a high-quality offspring (a foreign  one): MSG PL95. This strain was used in all 
experiments. Similarly to the case of other medicinal mushrooms (Ganoderma lucidum or Grifola 
frondosa or P. pulmonarius), we have chosen a potato extract as crop environment [18]. This 
environment offers many advantages regarding the quality of mycelium culture in vitro. The seed 
cultures were grown in 250 mL flasks containing 50 mL of medium containing (g·L
-1) 20 sucrose,  
3 yeast extract, 10 peptone, 0.1 NaNO3, 0.3 K2HPO4, 0.5 MgSO4 and 0.2 at 25 °C in a rotatory 
incubator (Gallenkamp Orbital Incubator, UK) at 120 rpm for 21 days (with the constant pH of 5.5).  
 
3.1.2. Preparation of polysaccharides extracts 
 
The fermented broth was separated and concentrated at 40 °C to a small volume (20 mL) using a 
rotatory evaporator under reduced pressure (vacuum pump). Samples were filtered and then 95 and 
75% ethyl alcohol (1:4, v/v) was successively added to the filtrate. The mixture of extracellular 
fractions (EF) was centrifuged at 7000 x g for 20 min to collect the precipitate, (with a yield of  
35.7 g/kg, dry weight), which was dissolved in water. After further purification through ultra filtration 
with membrane filter (0.7 μm) pore size, molecules of more than 10
5  Da were obtained and Int. J. Mol. Sci. 2009, 10                 
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lyophilized. In this study, this is referred to as water-soluble EF of P. ostreatus with extract of 
polysaccharides (EPS). The contents of EPS were determined by the phenol-sulfuric acid method [19]. 
In the experiments, the average content of EPS in EF was as 48 mg/100 mL liquid medium.  
 
3.1.3. Animals 
 
We have used for all experiments commercial broilers (Ross-type, 308), raised in isolation units of 
the Clinic for Poultry, University Science of Agriculture and Veterinary Medicine, Timişoara, 
Romania. The parents had been vaccinated once with IBDV live vaccine. Feed and water were 
provided ad libitum. For feeding the chickens a combined fodder has been used. The ingredients: corn, 
wheat, soja, monocalcium phosphate, calcium carbonate, mineral-vitamin premix, salt, plus, 
respectively, the analytic constituents: raw protein (min. 21.57%), raw fat (min. 4.81%), raw cellulose 
(max. 3.35%), raw ash (max. 2.60%), methionine (0.58%). 
 
3.1.4. The BIAVAC vaccine 
 
The BIAVAC vaccine is a live, lyophilised, monovalent vaccine, obtained from an intermediary 
bursal virus stem cultivated on of non-vaccinated hen embryos. The minimum titer is 3.5 log10 EID50 
(mean embryo infective dose) for each vaccine dose. The induced immunity, according to the 
manufacturer is developed within 8 to 14 days from date of vaccination. BIAVAC vaccine can be 
administered subcutaneous, in the eye, in the water intake or through aerosols. This vaccine is used at 
the age when the level of maternal antibodies is in obvious decrease. The vaccine is produced by the 
SC Pasteur Institute SA (Bucarest, Romania). 
 
3.1.5. BIAROMVAC - PA vaccine 
 
This vaccine is prepared with the BIA–PA stem and it is used against the infectious bursal disease 
and does not assure complex immunity. Every vaccine dose contains the specific antigens and the 
protective support for lyophilisation. The specific antigen is an attenuated virus suspension of the 
infectious bursal disease, the BIA–PA stem, cultivated on embryonated non-vaccinated hen eggs and 
having a minimum titer of 3.5 log10 EID50. The protective support for lyophilisation contains a watery 
solution of 2% peptone and 10% lactose, i.e. one dose. The BIAROMVAC PA vaccine is used for 
preventing IBD in poultry-breeding districts where the infection pressure is particularly high and the 
disease has severe evolutions. The immunity induced by the BIAROMVAC PA vaccine develops in  
2–3 weeks after the administration and reaches the optimal level after the booster doses. The duration 
and the immunity level are influenced by the birds’ state of health, the zoo-hygiene conditions and the 
interval between vaccinations. The vaccination with BIAROMVAC PA confers protection to the 
chickens throughout the exploitation and to the laying hens for a normal period of laying. 
BIAROMVAC – PA vaccine is produced and marketed by the SC Romvac Company SA (Romania). 
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3.1.6. Experimental design 
 
The experiment took place over a period of five weeks and we used newly hatched chickens (one 
day old). The parents of those chickens had been immunised with BIA (Bursal infectious aviar virus) 
live vaccines. So these chickens were included our experiment with a certain dose of maternal 
antibodies. Within the experiment, we have used 180 broiler chickens from parents 30 weeks old, 
immunized against bursa with live vaccine. The 180 chickens have been divided in nine groups of  
20 chickens (Table 8). We have followed their maternal antibodies all along the experiment. For 
simplification, the groups have been named according to the treatment applied. The broiler chickens 
from the Control  experimental group have received for the duration of the experiment only food   
and water.  
In the aqueous diet of the new chickens we have administrated daily from dry weight EF, 50 and  
150 mg/100 mL water (w/v, that is 5 and 15%), which correspond to experimental variants (II, III, V, 
VI, VIII and IX) shown in Table 8. To the broiler chickens from experimental groups IV – IX, at the 
end of week 1, we have stopped the water diet for eight hours, and then the vaccines have been 
administered in the water intake. One dose has been administered to each broiler, respectively,   
3.5 log10 EID50 in the water intake. We have used for this purpose 60 doses of BIAVAC vaccine and, 
respectively, 60 of BIAROMVAC. We have assured a hydric diet of minimum four hours long 
throughout the experiment and a standard microclimate according to the age evolution for the 
chickens.  
 
Table 8. The experimental design. 
Experimental System  Descriptive details 
I.  Control  NV chickens (non-vaccinated) and no EF (extracellular fraction) treatment from Pleurotus 
II.  NV + 5% EF  NV chickens + treatment with 5% EF from Pleurotus 
III.  NV + 15% EF  NV chickens + treatment with 15% EF from Pleurotus 
IV.  BIAVAC Control  Vaccinated chicken with BIACAV vaccine and no EF treatment 
V.  BIAVAC + 5% EF  Vaccinated chicken with BIACAV vaccine + treatment with 5% EF 
VI.  BIAVAC + 15% EF  Vaccinated chicken with BIACAV vaccine + treatment with 15% EF  
VII.  BIAROMVAC Control  Vaccinated chicken with BIAROMCAV vaccine and no EF treatment  
VIII.  BIAROMVAC + 5% EF  Vaccinated chicken with BIAROMCAV vaccine + treatment with 5% EF 
IX.  BIAROMVAC + 15%EF  Vaccinated chicken with BIAROMCAV vaccine + treatment with 15% EF 
 
3.2. Analytical methods 
 
3.2.1. Estimation of infectious bursal disease antibodies 
 
In order to determine the antibodies titer, we have drawn blood samples from 20 chickens every 
week. From vaccinated chickens, blood samples have been taken before the vaccination and on day 
seven of each week afterwards. The blood has been drawn from the axillary vein. The serologic 
examination has been made for the two vaccines by using the immunoenzymatic test Flock Check Int. J. Mol. Sci. 2009, 10                 
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(ELISA test), using a kit of INDEXX Laboratories (USA), named Infectious Bursal Disease Virus 
Antibody Test Kit. The analyses have been made within the Laboratory of Virology, National Agency 
for Sanitary Veterinary and Food Safety, Timişoara, which is accredited by ISO quality system. The 
principle of the immunoenzymatic test meant to determine the relative level of anti BIA antibodies in 
chicken serum is the following. At the incubation of the serum diluted 1:500 (v/v) in the buckets of the 
micro-plate lined with viral antigen, anti-BIA antibodies from the serum (if they exist) form an 
antigen-antibodies complex with the antigen immobilized in the plate. After eliminating all loose 
material by washing, we have added the adjoint which adheres to the anti-BIA antibodies attached to 
the plate. The loose adjoint is eliminated by washing and then we have added the enzymatic sub layer. 
The color appeared as a result of the reaction is in direct proportion with the concentration of anti-BIA 
antibodies present in the sample. The optic density of each sample is analyzed with the help of 
spectrum-photometer, calibrated and verified at 650 nm, Tecan Sunrise (Tecan, Austria). The anti-BIA 
antibodies titer has been calculated in this respect according to the following formula:  
⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
+ = 36 . 3
P
S
log 09 . 1 T log
n
n
10 n 10   (13) 
where Tn = titer of antibodies, Sn = number of the serum sample and Pn = the mean of the positive 
controls.  
If the ratio Sn/Pn is superior to the value 0.2 (or the titer is higher than 396) the samples are positive 
and thus predict that the chickens have been vaccinated or have been exposed to the action of a virus, 
i.e. there is a immune response. With the help of this Infectious Bursal Disease Virus Antibody Test 
Kit, there can be identified even lower values of antibodies, even below the value of 396.  
 
3.2.2. Statistical analysis 
 
The data are shown as the mean ± SD. Data were conducted to SAS (STATGRAPHICS
® Centurion 
XV, USA, 2005) for analysis of variance (ANOVA). Statistical comparison within the groups and 
between groups of data was carried out using the Tukey’s HSD multiple range test was used to 
determine significant differences (P<0.05) among treatments.  
 
4. Conclusions 
 
We have shown the immunomodulatory effects of EF which contain polysaccharides from   
P. ostreatus against IBDV. In the first experiment (Control), where we have used non-vaccinated and 
non-EF treated, the level of IBD maternal antibodies has decreased very fast, even from the first days 
of post hatching. By administering EF from P. ostreatus there had place a stimulation of the 
production of IBD antibodies, approximately to half of the value of maternal antibodies titer from the 
first day of hatching. In experimental groups 2 and 3, although the broilers have been vaccinated with 
BIAVAC and BIAROMVAC vaccine, respectively, the maternal antibodies titer has been low, the 
chickens being almost devoid of antibodies. By adding EF, 5 and 15%, in the water intake, as 
compared to the immune system reaction in experiment 1, the level of IBD antibodies has increased. 
This has determined us to believe that using this combination of BIAVAC and BIAROMVAC vaccine Int. J. Mol. Sci. 2009, 10                 
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and EF from P. ostreatus is good for antibodies production stimulation in the period of the first days of 
life. In this period, according to the latest researches, it appears that the vaccines show affinity and 
associate with B cells, macrophages, and folliculars dendritic cells in bursa and spleen. The 
experiments have been rationalized by employing the parabolic chemical reactivity principles of 
electronegativity and chemical hardness indices to formulate and apply the ReBiAc counterparts.  
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